A comparative review of inflammatory bowel disease guidelines: JSGE, ECCO, AGA, and ACG
EXCLI Journal · 29.09.2026 · 25 · 1516-1526
DOI: 10.17179/excli2026-9575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 29.09.2026. Verfasst von Yuta Shimomori und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University, S-1, W-16, Chuo-ku, Sapporo 060-8543, Hokka…. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Inflammatory bowel disease (IBD), encompassing ulcerative colitis (UC) and Crohn’s disease (CD), is managed according to clinical practice guidelines that integrate evidence appraisal with regional healthcare contexts. This narrative, comparative review examined selected guideline documents from the Japanese Society of Gastroenterology (JSGE), European Crohn’s and Colitis Organisation (ECCO), American Gastroenterological Association (AGA), and American College of Gastroenterology (ACG) using the JSGE guidelines as the organizing framework to highlight similarities and differences in recommendation direction and contextual nuance. The analysis focused on the guideline architecture and selected domains of monitoring and medical therapy, with particular attention to how document structure, scope, publication timing, and update strategies shape the interpretation of similarities and differences in recommendation direction. Across the guideline systems, general agreement in overall direction was observed regarding the shift from symptom-based assessment alone towards objective monitoring, the sustained role of 5-aminosalicylic acid (5-ASA) in the treatment of UC, the expanding integration of advanced therapies, and the adoption of risk-based surveillance principles for IBD-associated colorectal neoplasia. The most notable divergence concerned the use of 5-ASA in CD treatment: the JSGE guidelines retained a more pragmatic role for this therapy, whereas the recent ECCO, AGA, and ACG guidelines generally limited routine use. Treatment withdrawal and de-escalation emerged as particularly heterogeneous domains, reflecting the uneven treatment of drug-specific recommendations. The JSGE guidelines were notable for their distinctive single-volume integration of diagnostic criteria, treatment strategy, and follow-up, as well as their explicit inclusion of Japan-specific considerations, such as nucleoside diphosphate-linked moiety X-type motif 15 genotyping, cytapheresis, and oral tacrolimus. These findings suggest that apparent differences among IBD guidelines should be understood not only as differences in clinical judgment, but also as products of guideline architecture, update timing, and intended scope.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Sapporo Medical University, S-1, W-16, Chuo-ku, Sapporo 060-8543, Hokkaido, Japan.
- Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu 879-5593, Oita, Japan.
Zitieren
APA
Shimomori, Y., Yokoyama, Y., Akita, K., Kazama, T., Wagatsuma, K., Mizukami, K., & Nakase, H. (2026). A comparative review of inflammatory bowel disease guidelines: JSGE, ECCO, AGA, and ACG. EXCLI Journal, 25, 1516-1526. https://doi.org/10.17179/excli2026-9575
Vancouver
Shimomori Y, Yokoyama Y, Akita K, Kazama T, Wagatsuma K, Mizukami K, et al. A comparative review of inflammatory bowel disease guidelines: JSGE, ECCO, AGA, and ACG. EXCLI Journal. 2026;25:1516-1526. doi:10.17179/excli2026-9575
BibTeX
@article{Shimomori2026,
author = {Shimomori, Yuta and Yokoyama, Yoshihiro and Akita, Kotaro and Kazama, Tomoe and Wagatsuma, Kohei and Mizukami, Kazuhiro and Nakase, Hiroshi},
title = {A comparative review of inflammatory bowel disease guidelines: JSGE, ECCO, AGA, and ACG},
journal = {EXCLI Journal},
year = {2026},
volume = {25},
pages = {1516--1526},
doi = {10.17179/excli2026-9575}
}
EUVIMED